Cargando…
Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
The global emergency caused by COVID-19 makes the discovery of drugs capable of inhibiting SARS-CoV-2 a priority, to reduce the mortality and morbidity of this disease. Repurposing approved drugs can provide therapeutic alternatives that promise rapid and ample coverage because they have a documente...
Autores principales: | Jiménez-Alberto, Alicia, Ribas-Aparicio, Rosa María, Aparicio-Ozores, Gerardo, Castelán-Vega, Juan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316061/ https://www.ncbi.nlm.nih.gov/pubmed/32623357 http://dx.doi.org/10.1016/j.compbiolchem.2020.107325 |
Ejemplares similares
-
Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
por: Tripathi, Praveen Kumar, et al.
Publicado: (2020) -
Design of a Multi-Epitope Vaccine against Tuberculosis from Mycobacterium tuberculosis PE_PGRS49 and PE_PGRS56 Proteins by Reverse Vaccinology
por: Ruaro-Moreno, Maritriny, et al.
Publicado: (2023) -
The hemagglutinin of the influenza A(H1N1)pdm09 is mutating towards stability
por: Castelán-Vega, Juan A, et al.
Publicado: (2014) -
Analysis of Adaptation Mutants in the Hemagglutinin of the Influenza A(H1N1)pdm09 Virus
por: Jiménez-Alberto, Alicia, et al.
Publicado: (2013) -
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)